Limited Competition: CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
ID: 356637Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356637

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PA-25-093.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a limited competition grant opportunity titled "CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin," aimed at funding fundamental research on skin injuries caused by chemical threats recognized as public health risks. The initiative seeks to enhance understanding of the mechanisms leading to chemical-induced skin injuries and to identify potential therapeutic targets for medical countermeasure development, with a focus on examining two or more Chemicals of Concern, including at least one vesicant. This funding opportunity is crucial for advancing knowledge in the field of chemical threat response and wound healing, with an estimated funding amount of $1.25 million available for fiscal year 2025, allowing for up to five awards capped at $225,000 per year. Applications will open on January 16, 2025, and interested parties can direct inquiries to grantsinfo@nih.gov for further information.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PA-25-093.html
    The Department of Health and Human Services is offering a limited competition funding opportunity titled "CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin" under the R34 Planning Grant activity code. This initiative, supported by the National Institutes of Health and specifically the National Institute of Arthritis and Musculoskeletal and Skin Diseases, aims to fund fundamental research focused on skin injuries from chemical threats recognized as public health risks. The goal is to enhance knowledge of the mechanisms that lead to chemical-induced skin injuries and to identify potential therapeutic targets for medical countermeasure development. The application process opens on January 16, 2025, with an estimated funding amount of $1.25 million for fiscal year 2025, allowing up to five awards with direct costs capped at $225,000 per year. Eligible applicants include higher education institutions, nonprofits, and governmental entities, among others. The proposed research must examine two or more Chemicals of Concern, including at least one vesicant. The funding opportunity encourages innovative research without requiring preliminary data but emphasizes the need for prior experience in wound healing research. Applications will be evaluated based on scientific merit, with a focus on the significance, innovation, and feasibility of the proposed work.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Limited Competition: Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) aimed at promoting research on skin injuries caused by chemical threats, as part of the Chemical Countermeasures Research Program (CCRP). This initiative, led by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), seeks to investigate the commonalities of such injuries and identify potential therapeutic targets for medical countermeasure development. The NOFO is expected to be published in Fall 2024, with applications due in Winter/Spring 2025, and will offer a funding ceiling of $450,000. Interested applicants should prepare to submit their proposals by the estimated close date of February 16, 2025, with awards anticipated to be made by December 1, 2025.
    CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) titled "CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms," aimed at supporting research into the mechanisms of chemical toxicity affecting the lungs and eyes. This initiative seeks to fund projects that explore the health impacts of chemical threat agents, with a focus on identifying molecular and genetic targets for therapeutic countermeasures, utilizing various research methodologies such as animal models and computational modeling. A total of approximately $3 million is available to support up to five grants, with each project eligible for a maximum budget of $300,000 per year over a three-year period. Interested applicants should note that the application period opens on August 24, 2024, with a final submission deadline of September 24, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Basic Research on Chemical Threats that Affect the Nervous System (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) program, focusing on basic research related to chemical warfare agents and toxic industrial chemicals that impact the nervous system. The objective is to elucidate mechanisms of toxicity, identify biological markers, and develop potential therapeutic countermeasures for civilian populations exposed to these chemicals. This funding opportunity is critical for enhancing public safety against chemical threats, with a total of $2 million available for up to four awards, each with a maximum annual budget of $300,000 over three years. Interested applicants must submit their proposals by September 17, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the CCRP Initiative for Countermeasures Against Chemical Threats (CounterACT), aimed at supporting translational exploratory/developmental research projects that advance novel medical countermeasures (MCMs) for serious health impacts resulting from acute exposure to toxic chemical threats. The initiative specifically seeks projects that develop or repurpose existing FDA-approved products as potential treatments, generating preliminary data necessary for broader NIH support, while excluding basic research or environmental decontamination technologies. This funding opportunity has a ceiling of $275,000 over a two-year period, with applications due by May 30, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) plans to publish a Notice of Funding Opportunity (NOFO) for the Countermeasures Against Chemical Threats (CounterACT) initiative, focusing on the early-stage development of therapeutics to address health impacts from toxic chemical exposure. This funding opportunity aims to foster collaborations and innovative projects that can effectively mitigate adverse health effects, with an emphasis on the UG3/UH3 activity code for phased development. The NOFO is anticipated to be released in early 2025, with applications due by October 2025, and awards expected to be made by June 2026, marking a significant investment in public health safety. Interested applicants should prepare to align their proposals with the outlined objectives and timelines.
    Chemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity under the Chemical Countermeasures Research Program (CCRP) to support basic research on the deleterious effects of acute exposure to ultra-potent synthetic (UPS) opioids. This initiative aims to identify and validate mechanisms, signaling pathways, and therapeutic targets to understand and mitigate the toxic effects and long-term health consequences associated with UPS opioid overdoses, particularly focusing on respiratory depression and related complications. With a total funding allocation of $2.5 million for fiscal year 2023, the NIH plans to fund up to six applications, emphasizing innovative collaborative research approaches to address critical public health challenges posed by synthetic opioids. Interested applicants must submit their proposals by November 19, 2024, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems) (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Development of Alternative Human Models of Radiation-Induced Injuries (Extracorporeal Systems)" aimed at supporting research into acute and delayed radiation injuries. This initiative seeks to develop innovative extracorporeal systems that accurately replicate human responses to radiation, facilitating the exploration of injury mechanisms and the testing of medical countermeasures. The funding, structured as a U01 cooperative agreement, has a total budget of $4 million, with plans to award six to eight grants in FY 2026. Interested applicants should note that the submission deadline is February 7, 2025, and they can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Clinical Observational (CO) Studies focused on musculoskeletal, rheumatic, and skin diseases, under the grant title PAR-24-036. This grant, which does not allow clinical trials, aims to support observational studies that collect critical data to inform future clinical research, particularly regarding disease symptoms, progression, and participant eligibility, while also exploring telehealth and digital outcomes. The initiative is designed to enhance the rigor of future clinical trials through comprehensive data collection from diverse populations, ultimately improving patient outcomes in affected communities. The grant provides up to $475,000 over four years, with applications opening on February 4, 2024, and funding decisions expected by late 2024. Interested applicants can find more information and guidelines at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the R21 grant titled "Novel Approaches for Radiation Biodosimetry and Medical Countermeasure Development," aimed at supporting exploratory research projects focused on radiation exposure and its medical countermeasures. The initiative seeks innovative proposals that address the development of biodosimetry techniques, medical countermeasures for radiation injuries, and animal model development, with an emphasis on high-risk, high-reward research that can enhance public health emergency preparedness. The total funding available is approximately $2 million, with individual awards capped at $100,000 per year for a maximum of two years. Interested applicants must submit their proposals by November 1, 2024, and can direct inquiries to grantsinfo@nih.gov for further information.
    HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the HEAL Initiative, titled "Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)." This initiative aims to support early-stage translational research focused on developing and validating tests for non-opioid analgesics, including small molecules and biologics, to address the ongoing opioid crisis and improve pain management. The program anticipates a funding pool of $2.5 million, with plans to award approximately 4-5 grants in FY 2025, and applications are due by January 15, 2027. Interested applicants can find more information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.